Note that we do NOT copy edit or otherwise change supplementary information, and minor (nonfactual) errors in these documents cannot be corrected after publication. Please submit document(s) exactly as you want them to appear, with all text, images, legends and references in the desired order, and check carefully for errors.
(add rows as necessary)

Title or Caption
Supplementary Figure 1 Summary of selected Pin1 substrates Supplementary Figure 2 Characterization of the interaction between Pin1 and HTS probe pTide or ATRA Supplementary Figure 3 ATRA-dose-dependently binds and fully inhibits Pin1, but not Cyclophilin or FKBP12 Supplementary Figure 4 The carboxylic group of ATRA as a pharmacophore for binding to Pin1 and co-crystal structure of ATRA and Pin1 PPIase domain Supplementary Figure 5 Characterization of the ability of the pan-RAR activator AC-93253, the pan-RAR inhibitor Ro-415253, and ATRA to bind Pin1 and transactivate RAR downstream target genes Supplementary Figure 6 Pin1 interacts with PML-RAR-α containing S581 and increase PML-RAR-α protein stability in NB4 cells Supplementary Figure 7 Pin1 interacts with PML-RAR-α but much less with PLZF-RAR-α, and Pin1 knockdown reduces protein stability of PML-RAR-α but much less on PLZF-RAR-α in NB4 Supplementary Figure 8 Doxycycline-induced Pin1 KD or other structurally distinct Pin1 inhibitors effectively inhibits spleen size or cell proliferation of transplanted APL cells Supplementary Figure 9 ATRA induces Pin1 and PML-RAR-α degradation in vitro Supplementary Figure 10 Ser71 phosphorylation prevents ATRA from interacting with Pin1, and cytochrome P450 inhibitor, pan-RAR activator or inhibitor has no obvious effect on the ability of ATRA to inhibit cell growth or to induce Pin1 or cyclin D1 degradation of human breast cancer cells
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Supplementary Figure 11 Summary schemes Supplementary Table 1 Data collection and refinement statistics Supplementary Table 2 Fold change of transcripts in ATRA-treated or Pin1 knockdown NB4 cells Supplementary Table 3 Patient information on APL human samples Supplementary Table 4 Patient information on triple negative breast cancer human samples Supplementary Methods 
